Market closed
Catalyst Pharmaceuticals/$CPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Ticker
$CPRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
181
Website
CPRX Metrics
BasicAdvanced
$3B
18.53
$1.31
0.79
-
Price and volume
Market cap
$3B
Beta
0.79
52-week high
$26.16
52-week low
$14.47
Average daily volume
1.4M
Financial strength
Current ratio
5.168
Quick ratio
4.831
Long term debt to equity
0.383
Total debt to equity
0.438
Management effectiveness
Return on assets (TTM)
18.46%
Return on equity (TTM)
29.38%
Valuation
Price to earnings (TTM)
18.527
Price to revenue (TTM)
5.847
Price to book
4.03
Price to tangible book (TTM)
5.14
Price to free cash flow (TTM)
12.016
Growth
Revenue change (TTM)
23.49%
Earnings per share change (TTM)
107.94%
3-year revenue growth (CAGR)
51.71%
3-year earnings per share growth (CAGR)
52.41%
What the Analysts think about CPRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.
CPRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CPRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CPRX News
AllArticlesVideos
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
GlobeNewsWire·3 days ago
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewsWire·2 weeks ago
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $3B as of May 03, 2025.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 18.53 as of May 03, 2025.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.